Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Arcadia Biosciences (RKDA) Announces First-Quarter 2021 Financial Results and Business Highlights

      -- Revenues up for the quarter over 160%, liquidity strengthened --

      -- Acquires Lief assets, a premium portfolio of CBD and wellness brands, bringing immediate top-line revenue, manufacturing capabilities, retail network and proven leadership in consumer goods industry --

      -- Acquires European food ingredient platform enhancing GoodWheat business and broadening market access in Europe --

      Arcadia Biosciences Logo (PRNewsfoto/Arcadia Biosciences, Inc.)

      News provided by

      Arcadia Biosciences, Inc.

      May 17, 2021, 16:05 ET

      Share this article

      Share this article


      DAVIS, Calif., May 17, 2021 /PRNewswire/ -- Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a leader in science-based approaches to enhancing the quality and nutritional value of crops and food ingredients, today released its financial and business results for the first quarter of 2021.

      "With our acquisition of select assets of Lief Holdings, LLC and Live Zola, LLC  announced today, we added to our business a well-established portfolio of best-in-class CBD-infused and wellness products generating $6 million in recurring annual revenues with strong growth potential, and we gained access to a national distribution network offering retail sales synergies with our GoodWheat™ and GLA consumer products," said Matt Plavan, CEO of Arcadia. "In line with our stated strategy to increase our verticalization and maximize control over our supply chain to ensure quality from seed to sale and to participate more fully in the value of the brands for our proprietary innovations, the Lief manufacturing capability and distribution into over 5,000 retail doors delivers resoundingly on that strategy."

      Recent Operating and Business Highlights

      • Arcadia Acquires Portfolio of CBD Wellness Brands from The Parent Company. Arcadia announced today that it has acquired select assets of Lief and Zola, including their portfolio of wellness brands from The Parent Company. The acquisition includes leading consumer brands like Soul SpringTM, the top selling CBD-infused botanical therapy brand in the natural category, Saavy NaturalsTM, a leading line of all-natural body care products, Zola®, a leading coconut water sourced exclusively with sustainably grown coconuts from Thailand, and ProvaultTM, a CBD-infused sports performance formula providing effective support and recovery for athletes. As part of the transaction, Arcadia gains access to distribution channels and relationships in more than 5,000 stores nationally, the Lief manufacturing operations, which occupy a 20,000 square foot, GMP-licensed, ISO-certified manufacturing facility, as well as an experienced senior management team who brings years of expertise and success in the fast-moving consumer goods industry.
      • Belinda Yao Joins Arcadia as Vice President of Operations. Arcadia recently announced the hiring of Belinda Yao as VP of operations to oversee supply chain manufacturing for the company, including demand planning, procurement and supplier relationships, order fulfillment, inventory management, logistics, customer service and data analytics. Yao is a former supply chain lead for The Dannon Company, Harmless Harvest and Live Zola, and she will expand Arcadia's ability to drive direct-to-consumer sales for GoodWheat, GoodHemp™ and SONOVA® GLA safflower oil products, as well as the newly acquired portfolio of wellness products.
      • Arcadia Acquires European Food Ingredient Platform, Enhancing GoodWheat Business and Broadening Market Access in Europe. In April 2021, through Arcadia SPA, S.L., Arcadia acquired the assets of Agrasys S.A, a food ingredients company based in Barcelona, Spain. The transaction includes the physical and intellectual property assets to commercialize Tritordeum, a proprietary combination of durum wheat and wild barley, resulting in a nutritious cereal grain that is high in fiber, protein and antioxidants. Agrasys' network includes more than 50 grain producers and 25 millers and distributors, commercializing Tritordeum in 10 countries with seven retailers in Europe, most recently launching with Albert Heijn, the largest grocery retailer in Holland.
      • Health Canada Approves GoodHemp Seed Varieties, Enabling Sales in Canada. Also in April, Arcadia announced that three of its GoodHemp™ varieties – Rogue, Umpqua and Santiam – earned approval from Health Canada for their consistency and compliance. The approval is the final step to enable hemp seed sales in Canada. GoodHemp seed varieties and genetics are distributed in Canada by Tritium 3H, Inc. (T3H), which specializes in hemp field testing, certified seed production, commercialization and distribution of industrial hemp varieties. The approval from Health Canada broadens the geographic opportunities for GoodHemp and enables growers to access high quality seeds through Tritium for the 2021 growing season.
      • GoodHemp Seed Varieties Earn AOSCA Certification. Arcadia announced in February that four of its GoodHemp varieties – Rogue, Umpqua, Santiam and Potomac – have all passed the rigorous standards of the national Association of Official Seed Certifying Agencies (AOSCA) variety review board. The variety review is conducted by representatives of seed certifying agencies, academia, the seed industry and USDA to make certain new varieties are distinct, uniform and stable. AOSCA certification signifies to the industry that GoodHemp seed is produced to the highest standards for genetic purity, uniformity, high germination and feminization rates and varietal identity. It also enables sales in states such as Florida, that require AOSCA certified hemp seed for planting.
      • Leading Consumer Food Industry Executive Joins Board. Debbie Carosella, a prominent consumer food industry executive, joined Arcadia's board of Directors in February 2021. Carosella is the former CEO of Madhava Natural Sweeteners, a company that provides natural alternatives to refined sugars and artificial sweeteners. A recognized leader in the natural and organic food industry, she previously served as the senior vice president of innovation for Dean Foods/ WhiteWave Foods where she led the development of value-added brands across the company. Prior to that, Carosella was on the executive leadership team at ConAgra Foods where she was both a general manager and innovator for numerous brands in a multitude of food categories.
      • $25.1 Million Private Placement Priced At the Market. In January 2021, Arcadia closed a private placement priced at-the-market with gross proceeds of $25.1 million. The funds will be used for general corporate purposes, including building Arcadia's global GoodWheat family of consumer brands, development of its e-commerce, direct-to-consumer digital marketing infrastructure to launch branded pasta, flour and other products, and to fund its Archipelago Ventures Hawaiian hemp cultivation and mainland CBD extraction operations.
      • E-commerce and Retail Platforms Established for GoodWheat Pasta and Flour. Arcadia entered 2021 with a functioning e-commerce website, and an SEO and digital media marketing plan to begin the design, test, and prove cycles needed to confirm its e-commerce scale-up strategy. The company began that effort in mid-February of this year. Initial results were very favorable in driving traffic to the site, but initially, with sub-par sales conversion. Modifications were made to the SEO formulas and the company recently saw much better conversion rates. Arcadia will continue its optimization efforts and expects to substantially increase ad spend later in the year to drive increased sales volumes.

      Arcadia Biosciences, Inc.

      Financial Snapshot

      (Unaudited)

       ($ in thousands)



      Three Months Ended March 31,


      2021

      2020

      Favorable / (Unfavorable)






      $


      %

      Total Revenues

      828


      309


      519


      168%

      Total Operating Expenses

      6,154


      6,099


      (55)


      (1)%

      Loss From Operations

      (5,326)


      (5,790)


      464


      8%

      Net Income Attributable to
      Common Stockholders

      2,058


      2,525


      (467)


      (19)%

      Revenues
      In the first quarter of 2021, revenues were $828,000, compared to revenues of $309,000 in the first quarter of 2020. The quarter-over-quarter increase was driven by GoodWheat grain sales and higher GLA product sales.

      Operating Expenses
      In the first quarter of 2021, operating expenses were $6.2 million, compared to $6.1 million in the first quarter of 2020. Research and development (R&D) spending decreased by $1.1 million in the first quarter of 2021, mostly due to lower employee expenses and the absence of Verdeca related activity in 2021 as our portion of the joint venture was sold to Bioceres in November 2020. General and administrative (SG&A) costs for the first quarter of 2021 were $346,000 higher than the first quarter in 2020, primarily driven by higher employee expenses and increased commercial activities, partially offset by less stock compensation for consultants. Cost of product revenues was $856,000 in the first quarter of 2021 as compared to $132,000 in the first quarter of 2020, the increase primarily the result of additional sales.

      Net Income Attributable to Common Stockholders
      Net income attributable to common stockholders for the first quarter of 2021 was $2.1 million, or $0.11 per share, a $467,000 decrease from the $2.5 million, or $0.29 per share, of net income for the first quarter of 2020. The first quarter of 2021 included $322,000 of non-cash income recognized as a result of the decrease in the fair value of common stock warrant liabilities while the first quarter of 2020 included $8.2 million of non-cash income for this same item. Non-cash income of $7.5 million was recorded in the first quarter of 2021 for the increase in the fair market value of the shares of Bioceres stock held, but no such income was recorded in the first quarter of 2020 as the stock was acquired in November 2020.

      Conference Call and Webcast
      The company has scheduled a conference call for 4:30 p.m. Eastern (1:30 p.m. Pacific) today, May 17, to discuss first-quarter financial results and key strategic achievements.

      Interested participants can join the conference call using the following numbers:

      U.S. Toll-Free Dial-In:             +1-844-243-4690
      International Dial-In:                +1-225-283-0138
      Passcode:                               7782155

      A live webcast of the conference call will be available on the "Investors" section of the Arcadia website at www.arcadiabio.com. Following completion of the call, a recorded replay will be available on the company's investor website.

      About Arcadia Biosciences, Inc.
      Arcadia Biosciences (Nasdaq: RKDA) is a leader in science-based approaches to enhancing the quality and nutritional value of crops and food ingredients. The company's GoodWheat™ branded ingredients deliver health benefits to consumers and enable consumer packaged goods companies to differentiate their brands in the marketplace. The company's GoodHemp™ seed catalog delivers genetically superior hemp seeds, transplants and extracts, bringing the benefits of modern agriculture to an emerging crop. For more information, visit www.arcadiabio.com.

      Safe Harbor Statement 
      "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This press release and the accompanying conference call contain forward-looking statements about the company and its products, including statements relating to projected revenue growth as a result of the asset acquisition. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the price and demand for the company's products are lower than expected; the company's and its partners' and affiliates' ability to develop and sell commercial products incorporating its traits, and complete the regulatory review process for such products; the company's compliance with laws and regulations that impact the company's business, including the sale of products containing CBD and changes to such laws and regulations; the growth of the global wheat and hemp markets; the successful integration of the acquired brands and assets into Arcadia's business; the potential impact of COVID-19 on the company's business; and the company's future capital requirements and ability to satisfy its capital needs. Further information regarding these and other factors that could affect the company's financial results is included in filings the company makes with the Securities and Exchange Commission from time to time, including the section entitled "Risk Factors" and additional information set forth in its Form 10-K for the year ended December 31, 2020, and other filings. These forward-looking statements speak only as of the date hereof, and Arcadia Biosciences, Inc. undertakes no duty to update these forward-looking statements.

      Arcadia Biosciences, Inc.

      Condensed Consolidated Balance Sheets

      (Unaudited)

      (In thousands, except share data)



      March 31, 2021


      December 31, 2020

      Assets




      Current assets:




      Cash and cash equivalents

      32,848


      $14,042

      Short-term investments

      19,088


      11,625

      Accounts receivable

      1,113


      1,406

      Inventories, net — current

      2,663


      3,812

      Prepaid expenses and other current assets

      901


      811

      Total current assets

      56,613


      31,696

      Restricted cash

      -


      2,001

      Property and equipment, net

      3,480


      3,539

      Right of use asset

      5,636


      5,826

      Inventories, net — noncurrent

      4,290


      3,485

      Goodwill

      408


      408

      Intangible assets, net

      350


      370

      Other noncurrent assets

      23


      23

      Total assets

      $                 70,800


      $                  47,348

      Liabilities and stockholders' equity




      Current liabilities:




      Accounts payable and accrued expenses

      $                   3,418


      $                    4,105

      Amounts due to related parties

      26


      80

      Debt — current

      1,141


      1,141

      Unearned revenue — current

      63


      8

      Operating lease liability — current

      705


      717

      Other current liabilities

      264


      263

      Total current liabilities

      5,617


      6,314

      Debt — noncurrent

      96


      2,105

      Operating lease liability — noncurrent

      5,228


      5,389

      Common stock warrant liabilities

      12,016


      2,708

      Other noncurrent liabilities

      2,140


      2,280

      Total liabilities

      25,097


      18,796

      Stockholders' equity:




         Common stock, $0.001 par value—150,000,000 shares 
         authorized as of March 31, 2021 and December 31, 2020;

         21,336,249 and 13,450,861 shares issued and outstanding as of

         March 31, 2021 and December 31, 2020, respectively

      62


      54

      Additional paid-in capital

      254,208


      239,496

      Accumulated deficit

      (209,767)


      (211,825)

      Total Arcadia Biosciences stockholders' equity

      44,503


      27,725

      Non-controlling interest

      1,200


      827

      Total stockholders' equity

      45,703


      28,552

      Total liabilities and stockholders' equity

      $                 70,800


      $                  47,348

      Arcadia Biosciences, Inc.

      Condensed Consolidated Statements of Operations and Comprehensive Income

      (Unaudited)

      (In thousands, except share and per share data)



      Three Months Ended March 31,


      2021


      2020

      Revenues:




      Product

      $                       803


      $                       154

      License

      -


      100

      Royalty

      25


      30

      Contract research and government grants

      —


      25

      Total revenues

      828


      309

      Operating expenses:




      Cost of product revenues

      856


      132

      Research and development

      1,159


      2.244

      Change in fair value of contingent consideration

      (140)


      —

      Write-down of fixed assets

      210


      —

      Selling, general and administrative

      4,069


      3,723

      Total operating expenses

      6,154


      6,099

      Loss from operations

      (5,326)


      (5,790)

      Interest expense

      (9)


      (3)

      Other income, net

      7,463


      72

      Issuance and offering costs

      (769)


      —

      Change in fair value of common stock warrant liabilities

      322


      8,161

      Net income before income taxes

      1,681


      2,440

      Income tax provision

      —


      (17)

      Net income

      1,681


      2,423

      Net loss attributable to non-controlling interest

      (377)


      (102)

      Net income attributable to common stockholders

      $                    2,058


      $                  2,525

      Net income per share attributable to common stockholders:




      Basic

      $                      0.11


      $                    0.29

      Diluted

      $                      0.11


      $                    0.29

      Weighted-average number of shares used in per share calculations:




      Basic

      18,970,250


      8,651,213

      Diluted

      19,042,962


      8,674,610

      Other comprehensive loss, net of tax




      Unrealized losses on investment securities

      —


      (1)

      Other comprehensive loss

      —


      (1)

      Comprehensive income attributable to common stockholders

      $                    2,058


      $                2,524

      Arcadia Biosciences, Inc.

      Condensed Consolidated Statements of Cash Flows

      (Unaudited)

      (In thousands)



      Three Months Ended March 31,


      2021


      2020

      CASH FLOWS FROM OPERATING ACTIVITIES:




      Net income

      $                    1,681


      $                2,423

      Adjustments to reconcile net income to cash used in operating activities:




      Change in fair value of common stock warrant liabilities

      (322)


      (8,161)

      Change in fair value of contingent consideration

      (140)


      —

      Issuance and offering costs

      769


      —

      Depreciation

      236


      74

      Amortization of intangible assets

      20


      —

      Lease amortization

      289


      223

      Net amortization of investment premium

      —


      (39)

      Stock-based compensation

      325


      772

      Unrealized gain on corporate securities

      (7,463)


      —

      Write-down of fixed assets

      210


      —

      Write-down of inventory

      160


      59

      Changes in operating assets and liabilities:




      Accounts receivable

      293


      293

      Inventories

      184


      (4,145)

      Prepaid expenses and other current assets

      (90)


      (748)

      Other noncurrent assets

      —


      (15)

      Accounts payable and accrued expenses

      (591)


      227

      Amounts due to related parties

      (54)


      (24)

      Unearned revenue

      55


      (25)

      Other current liabilities

      3


      —

      Operating lease payments

      (272)


      (184)

      Net cash used in operating activities

      (4,707))


      (9,270)

      CASH FLOWS FROM INVESTING ACTIVITIES:




      Purchases of property and equipment

      (485)


      (778)

      Purchases of investments

      —


      (1,292)

      Proceeds from sales and maturities of investments

      —


      15,200

      Net cash (used in) provided by investing activities

      (485)


      13,130

      CASH FLOWS FROM FINANCING ACTIVITIES:




      Proceeds from issuance of common stock and warrants from January 2021 PIPE securities purchase agreement

      25,147


      —

      Payments of offering costs relating to January 2021 PIPE

      securities purchase agreement

      (1,912)


      —

      Principal payments on debt

      (2,009)


      (7)

      Proceeds from ESPP purchases

      21


      14

      Capital contributions received from non-controlling interest

      750


      689





      Net cash provided by financing activities

      21,997


      696

      Net increase in cash, cash equivalents and restricted cash

      16,805


      4,556

      Cash, cash equivalents and restricted cash — beginning of period

      16,043


      8,417

      Cash, cash equivalents and restricted cash — end of period

      $                  32,848


      $                12,973

      SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:




      Cash paid for income taxes

      $                          —


      $                         2

      Cash paid for interest

      $                         19


      $                         3

      NONCASH INVESTING AND FINANCING ACTIVITIES:




      Fixed assets acquired with notes payable

      $                         —


      $                       37

      Common stock warrants issued to placement agent and included in offering costs related to January 2021 PIPE securities purchase agreement

      $                      942


      $                       —

      Right of use assets obtained in exchange for new operating lease liabilities

      $                        —


      $                  3,836

      Purchases of fixed assets included in accounts payable and accrued expenses

      $                        25


      $                       —

      SOURCE Arcadia Biosciences, Inc.

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.